2022年英国风湿病学会《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南解读  

Understanding of “Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids” guideline by the British Society of Rheumatology in 2022

作　　者：姚蓉 董晓静[1] YAO Rong;DONG Xiaojing(Department of Gynecology and Obstetrics,Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院妇产科,重庆400010

出　　处：《现代医药卫生》2024年第1期1-9,共9页Journal of Modern Medicine & Health

基　　金：国家儿童健康与疾病临床医学研究中心临床医学研究一般项目(NCRCCHD-2020-GP-16)。

摘　　要：2022年11月2日英国风湿病学会(BSR)发布了《孕期和哺乳期用药-免疫调节抗风湿药物和皮质激素类药物》指南,该指南针对孕期和哺乳期处方抗风湿药物提供指导建议,内容包括抗疟药、糖皮质激素、传统合成的抗风湿药物(csDMARDs)和免疫制剂、生物制剂(bDMARDs)和靶向制剂(tsDMARDs)在妊娠期、哺乳期的安全性及对父亲用药的建议,补充了bDMARDs和tsDMARDs的推荐意见,旨在为医务人员使用该类药物提供依据。The British Society for Rheumatology(BSR) published “Prescribing drugs in pregnancy and breastfeeding:immunomodulatory anti-rheumatic drugs and corticosteroids” guideline on November 2,2022,the guideline provides the guidance suggestion on prescribing antirheumatic drugs during pregnant period and lactation period,the contents include the safety of antimalarials;corticosteroids;conventional synthetic DMARDs(csDMARDs) and immunosuppressive therapies;biologic DMARDs(bDMARDs);and targeted synthetic DMARDs(tsDMARDs) during pregnant period and lactation period,the recommendations for father medication,and replenish the recommendations for bMDARDs and tsDMARDs in order to provide a basis for the medical staff to use these kinds of drugs.

关 键 词：风湿免疫病 妊娠期 哺乳期 父亲 药物 安全性 

分 类 号：R287[医药卫生—中药学]